Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
Bawan Ahmed, Lecturer at University of Greenwich, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine, adding:
“Last week, the findings of the COBRRA trial, an important study in venous thromboembolism, were published in NEJM.
The data suggest that during the crucial initial 3-month treatment period, the risk of clinically significant bleeding was considerably lower with Apixaban, a factor Xa inhibitor, than with Rivaroxaban, another factor Xa inhibitor for the acute treatment of venous thromboembolism. Clinically relevant bleeding: 3.3% with apixaban vs 7.1% with rivaroxaban (RR 0.46; 95% CI 0.33–0.65; p < .001).
The findings could have an immediate impact on clinical practice globally for the management of acute DVT, particularly regarding the choice of DOAC.
In light of this, the following points are worth considering for clinical practice, as questions will arise, especially when most guidelines allow flexibility in prescribing both agents without indicating a preference.
For new cases, the superior safety profile of Apixaban makes a compelling case for its use as the preferred agent. If twice daily administration is not an issue.
Practicality of switch: If a patient is stable and beyond the acute phase, the benefits of switching should be balanced against the risks of moving from a once-daily to a twice-daily (BD) regimen. Non-adherence is the primary risk factor for sub-therapeutic anticoagulation post-switch.
In both cases, ensure creatinine clearance is appropriate!”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda